141 related articles for article (PubMed ID: 3500002)
1. An immunomodulating anti-rheumatic drug, lobenzarit disodium (CCA): inhibition of polyclonal B-cell activation and prevention of autoimmune disease in MRL/Mp-lpr/lpr mice.
Mihara M; Nakano T; Ohsugi Y
Clin Immunol Immunopathol; 1987 Dec; 45(3):366-74. PubMed ID: 3500002
[TBL] [Abstract][Full Text] [Related]
2. Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis.
Shiraki M; Fujiwara M; Tomura S
Clin Exp Immunol; 1984 Feb; 55(2):333-9. PubMed ID: 6607792
[TBL] [Abstract][Full Text] [Related]
3. Regulation of in vitro anti-DNA antibody production by a novel disease modifying anti-rheumatic drug, Lobenzarit.
Hirohata S
Clin Exp Rheumatol; 1992; 10(4):357-63. PubMed ID: 1356678
[TBL] [Abstract][Full Text] [Related]
4. A novel antifolate, MX-68, inhibits the development of autoimmune disease in MRL/lpr mice.
Mihara M; Takagi N; Urakawa K; Moriya Y; Takeda Y
Int Arch Allergy Immunol; 1997 Aug; 113(4):454-9. PubMed ID: 9250591
[TBL] [Abstract][Full Text] [Related]
5. Regulation of B cell function by lobenzarit, a novel disease-modifying antirheumatic drug.
Hirohata S; Shinohara S; Inoue T; Miyamoto T; Lipsky PE
Arthritis Rheum; 1992 Feb; 35(2):168-75. PubMed ID: 1734906
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulating effect of a traditional Japanese medicine, hachimi-jio-gan (ba-wei-di-huang-wan), on Th1 predominance in autoimmune MRL/MP-lpr/lpr mice.
Furuya Y; Kawakita T; Nomoto K
Int Immunopharmacol; 2001 Mar; 1(3):551-9. PubMed ID: 11367538
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of lupus dermatoses in autoimmune mice. XIX. Attempts to induce subepidermal immunoglobulin deposition in MRL/Mp- +/+ mice.
Furukawa F; Ohshio G; Imamura S
Arch Dermatol Res; 1993; 285(1-2):20-6. PubMed ID: 8470930
[TBL] [Abstract][Full Text] [Related]
8. Effect of several kinds of drugs on the development of autoimmunity in MRL/Mp-lpr/lpr mice; lack of correlation between the suppression of autoantibody production and prevention of autoimmune disease.
Mihara M; Ohsugi Y
J Pharmacobiodyn; 1989 Feb; 12(2):100-6. PubMed ID: 2526211
[TBL] [Abstract][Full Text] [Related]
9. Studies on the role of the lpr gene in the development of immunological abnormalities and lupus nephritis. Analyses in F2 mice.
Fujiwara M; Kariyone A; Shiraki M
Clin Exp Immunol; 1985 Jan; 59(1):161-8. PubMed ID: 3918816
[TBL] [Abstract][Full Text] [Related]
10. Effects of early and late treatment with anti-CD4 monoclonal antibody on autoimmune disease in MRL/MP-lpr/lpr mice.
Jabs DA; Kuppers RC; Saboori AM; Burek CL; Enger C; Lee B; Prendergast RA
Cell Immunol; 1994 Mar; 154(1):66-76. PubMed ID: 7907009
[TBL] [Abstract][Full Text] [Related]
11. Treatment of autoimmune MRL/Mp-lpr/lpr mice with cholera toxin.
Fan JL; Himeno K; Tsuru S; Nomoto K
Clin Exp Immunol; 1987 Oct; 70(1):94-101. PubMed ID: 3500817
[TBL] [Abstract][Full Text] [Related]
12. Effects of corticosteroid and 1,24R-dihydroxy-vitamin D3 administration on lymphoproliferation and autoimmune disease in MRL/MP-lpr/lpr mice.
Koizumi T; Nakao Y; Matsui T; Nakagawa T; Matsuda S; Komoriya K; Kanai Y; Fujita T
Int Arch Allergy Appl Immunol; 1985; 77(4):396-404. PubMed ID: 3874829
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with 5,5-diphenylhydantoin reduces lymphadenopathy and anti-ssDNA autoantibodies in C57BL/6-lpr/lpr mice.
Bloksma N; de Bakker JM; van Rooijen HJ; Punt P; Seinen W; Kammüller ME
Int J Immunopharmacol; 1994 Mar; 16(3):261-8. PubMed ID: 8206693
[TBL] [Abstract][Full Text] [Related]
14. Marked acceleration of the autoimmune disease in MRL-lpr/lpr mice by the influence of the Yaa gene from BXSB mice.
Miyawaki S; Nakamura Y; Takeshita T; Yoshida H; Shibata Y; Mitsuoka S
Lab Anim Sci; 1988 Jun; 38(3):266-72. PubMed ID: 2970562
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment of autoimmune MRL/MP-lpr/lpr mice with a herbal medicine, Ren-shen-yang-rong-tang (Japanese name: Ninjin-youei-to) plus suboptimal dosage of prednisolone.
Zhou NN; Nakai S; Kawakita T; Oka M; Nagasawa H; Himeno K; Nomoto K
Int J Immunopharmacol; 1994 Oct; 16(10):845-54. PubMed ID: 7843856
[TBL] [Abstract][Full Text] [Related]
16. [Functional analysis of an autoantigen reactive B cell clone derived from MRL/MP-lpr/lpr mice].
Kobayashi K; Hamano T; Kakishita E
Ryumachi; 1996 Dec; 36(6):844-55. PubMed ID: 9122824
[TBL] [Abstract][Full Text] [Related]
17. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.
Yan SX; Deng XM; Wang QT; Sun XJ; Wei W
Acta Pharmacol Sin; 2015 Nov; 36(11):1367-76. PubMed ID: 26456588
[TBL] [Abstract][Full Text] [Related]
18. Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn).
Takahashi T; Yagi T; Kakinuma S; Kurokawa A; Okada T; Takatsu K; Aizawa S; Katagiri T
J Immunol; 1997 Sep; 159(5):2532-41. PubMed ID: 9278347
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT).
Karussis DM; Vourka-Karussis U; Lehmann D; Abramsky O; Ben-Nun A; Slavin S
Clin Exp Immunol; 1995 Apr; 100(1):111-7. PubMed ID: 7697909
[TBL] [Abstract][Full Text] [Related]
20. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.
Watanabe H; Garnier G; Circolo A; Wetsel RA; Ruiz P; Holers VM; Boackle SA; Colten HR; Gilkeson GS
J Immunol; 2000 Jan; 164(2):786-94. PubMed ID: 10623824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
